Between genomic data, electronic health records and digital health tools, we have all the information we need to transform the fortunes of people living with cancer – but how do we ensure i
The EMA's human medicines committee has recommended against approval of Eisai and Biogen's Alzheimer's disease therapy Leqembi, after regulators in the US, China and Japan gave a green ligh